MRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer

Biological Chemistry

Volumn 392, Issue 11, 2011, Pages 1047-1051

  Kotzsch, Matthias ^a   Dorn, Julia ^b   Doetzer, Kristina ^b   Schmalfeldt, Barbara ^b   Krol, Janna ^b   Baretton, Gustavo ^a   Kiechle, Marion ^b   Schmitt, Manfred ^b   Magdolen, Viktor ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

ovarian cancer; prognosis; quantitative PCR; rab31; uPAR; uPAR del4 5

Indexed keywords

MESSENGER RNA; RAB 31 PROTEIN; RAB PROTEIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ADVANCED CANCER; ARTICLE; BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RAB GTP-BINDING PROTEINS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, MESSENGER;

EID: 80053626698     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2011.166     Document Type: Article

References (25)

1. Allgayer, H. (2010). Translational research on u-PAR. Eur. J. Cancer 46, 1241-1251.
2. Blasi, F. and Sidenius, N. (2010). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 584, 1923-1930.
3. Borgfeldt, C., Bendahl, P.O., Gustavsson, B., Långström, E., Fernö, M., Willén, R., Grenman, S., and Casslén, B. (2003). High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int. J. Cancer 107, 658-665. (Pubitemid 37296130)
4. Ceresa, B.P. (2006). Regulation of EGFR endocytic trafficking by rab proteins. Histol. Histopathol. 21, 987-993. (Pubitemid 44082742)
5. Cheng, K.W., Lahad, J.P., Kuo, W.L., Lapuk, A., Yamada, K., Auers-perg, N., Liu, J., Smith-McCune, K., Hu, K.L., Fishman, D., et al. (2004). The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat. Med. 10, 1251-1256. (Pubitemid 39540444)
6. Cheng, K.W., Lahad, J.P., Gray, J.W., and Mills, G.B. (2005). Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 65, 2516-2519. (Pubitemid 40490043)
7. Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L.R., Ploug, M., and Rømer, J. (2005). Plasminogen activation and cancer. Thromb. Haemost. 93, 676-681. (Pubitemid 40485402)
8. Dorn, J., Schmitt, M., Kates, R., Schmalfeldt, B., Kiechle, M., Sco-rilas, A., Diamandis, E.P., and Harbeck, N. (2007). Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin. Cancer Res. 13, 1742-1748. (Pubitemid 46952940)
9. Dorn, J., Harbeck, N., Kates, R., Gkazepis, A., Scorilas, A., Soo-saipillai, A., Diamandis, E., Kiechle, M., Schmalfeldt, B., and Schmitt, M. (2011). Impact of expression differences of kallik-rein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann. Oncol. 22, 877-882.
10. Henic, E., Borgfeldt, C., Christensen, I.J., Casslén, B., and Høyer-Hansen, G. (2008). Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin. Cancer Res. 14, 5785-5793.
11. Hutagalung, A.H. and Novick, P.J. (2011). Role of Rab GTPases in membrane traffic and cell physiology. Physiol. Rev. 91, 119-149.
12. Jones, M.C., Caswell, P.T., and Norman, J.C. (2006). Endocytic recycling pathways: emerging regulators of cell migration. Curr. Opin. Cell Biol. 18, 549-557. (Pubitemid 44349064)
13. Kenny, H.A., Leonhardt, P., Ladanyi, A., Yamada, S.D., Montag, A., Im, H.K., Jagadeeswaren, S., Shaw, D., Mazar, A.P., and Len-gyel, E. (2011). Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin. Cancer Res. 17, 459-471.
14. Kotzsch, M., Farthmann, J., Meye, A., Fuessel, S., Baretton, G., Tjan-Heijnen, V.C., Schmitt, M., Luther, T., Sweep, F.C., Mag-dolen, V., et al. (2005). Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. Eur. J. Cancer 41, 2760-2768. (Pubitemid 41607570)
15. Kotzsch, M., Sieuwerts, A.M., Grosser, M., Meye, A., Fuessel, S., Meijer-van Gelder, M.E., Smid, M., Schmitt, M., Baretton, G., Luther, T., et al. (2008). Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor. Breast Cancer Res. Treat. 111, 229-240.
16. Kotzsch, M., Magdolen, V., Greither, T., Kappler, M., Bache, M., Lautenschläger, C., Füssel, S., Eckert, A., Luther, T., Baretton, G., et al. (2011). Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system are correlated with disease-associated survival of soft-tissue sarcoma patients. BMC Cancer 11, 273.
17. Luther, T., Kotzsch, M., Meye, A., Langerholc, T., Füssel, S., Olbricht, N., Albrecht, S., Ockert, D., Muehlenweg, B., Friedrich, K., et al. (2003). Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer. Thromb. Haemost. 89, 705-717. (Pubitemid 36456968)
18. Mazar, A.P. (2008). Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin. Cancer Res. 14, 5649-5655.
19. Mengele, K., Napieralski, R., Magdolen, V., Reuning, U., Gkazepis, A., Sweep, F., Brünner, N., Foekens, J., Harbeck, N., and Schmitt, M. (2010). Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn. 10, 947-962.
20. Mosesson, Y., Mills, G.B., and Yarden, Y. (2008). Derailed endo-cytosis: an emerging feature of cancer. Nat. Rev. Cancer 8, 835-850.
21. Ragno, P. (2006). The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol. Life Sci. 63, 1028-1037. (Pubitemid 43800773)
22. Sato, S., Kopitz, C., Grismayer, B., Beaufort, N., Reuning, U., Schmitt, M., Luther, T., Kotzsch, M., Krüger, A., and Magdolen, V. (2011). Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo. Breast Cancer Res. Treat. 127, 649-657.
23. Smith, H.W. and Marshall, C.J. (2010). Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 11, 23-36.
24. Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nat. Rev. Mol. Cell Biol. 10, 513-525.
25. Wang, L., Madigan, M.C., Chen, H., Liu, F., Patterson, K.I., Beretov, J., O'Brien, P.M., and Li, Y. (2009). Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol. 114, 265-272.